Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.
about
Role of non-immune mechanisms of muscle damage in idiopathic inflammatory myopathiesMeasures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activityA systematic review of studies that aim to determine which outcomes to measure in clinical trials in childrenOutcomes in clinical trials of inhaled corticosteroids for children with asthma are narrowly focussed on short term disease activityDiagnosis and classification of idiopathic inflammatory myopathies.Evaluation of muscles affected by myositis using magnetic resonance elastography.Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference.Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathiesThe Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis.A longitudinal, integrated, clinical, histological and mRNA profiling study of resistance exercise in myositis.Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.Voluntary activation failure is detectable in some myositis patients with persisting quadriceps femoris weakness: an observational study.Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.Mass spectrometric determination of IgG subclass-specific glycosylation profiles in siblings discordant for myositis syndromesA randomized, pilot trial of etanercept in dermatomyositis.Assessment of patients with idiopathic inflammatory myopathies and isolated creatin-kinase elevation.Reliability of the adult myopathy assessment tool in individuals with myositisConsensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conferenceJuvenile dermatomyositis: new insights and new treatment strategies.Interpreting measurements of physical function in clinical trials.Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activityProposal for a Candidate Core Set of Fitness and Strength Tests for Patients with Childhood or Adult Idiopathic Inflammatory MyopathiesChanges in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease courseClinical assessment in juvenile dermatomyositis.Treatment of inflammatory myopathies.Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Physical Dysfunction after Treatment in Polymyositis and Dermatomyositis: An Observational Study of Physical Dysfunction with Myositis in JapanMagnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies.The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy.Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositisIdiopathic inflammatory myopathies: current and future therapeutic options.Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study.Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index.Serum adipocytokine profile and metabolic syndrome in young adult female dermatomyositis patients.Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease.Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositisPredictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.International consensus for a definition of disease flare in lupus.PET/CT imaging in inflammatory myopathies.Disease activity measures in paediatric rheumatic diseases
P2860
Q26830775-032295E7-CCC7-46E2-974C-C227C168EF42Q27021322-6C288130-94B4-47D3-B8BA-CC1E9F505CE8Q28087636-14C84D38-AAFD-4C0E-92CB-54171506062EQ28472665-149964D2-625E-417F-A8EB-D93AA6DF1993Q28475775-641B9A52-4AEB-41C7-850B-A009F4B81DECQ30249522-EA05B99A-9853-4435-9214-70B282EE01E7Q30469107-B9B4D8C6-8D3F-4BAB-A06F-139023071DB5Q34019438-5CA27557-4261-4A84-A896-A68DEEE2B287Q34074602-2257290A-4523-4EDC-AC0F-F49D68E70481Q34242363-1DEA597C-43B3-43AA-A69E-508DD1FAAD13Q34274225-47645CD3-0335-4CBC-835A-5A0CBEF98FEAQ34644962-F8D7D0C7-86B3-4054-BF13-33598DC07D3CQ34897588-941F2E76-F0AA-4641-8C57-DC4FF615128FQ35009335-C87FCC66-57EB-470C-AE65-F874B456AC52Q35108694-EE211339-659C-4F01-8056-E954A521768EQ35206687-D5A3A67E-6C7B-4728-8FCF-6594D2BEADA9Q35281980-FE7695EC-04D5-42C4-9AFE-227C3A341694Q35669132-89CF002D-9364-4C7A-B891-D4898EC6D431Q35861235-70EC9B16-D9F1-4419-9969-FBBBC187C921Q36059542-95B0608F-4688-4657-925B-4B5673719639Q36171753-57AC8987-310D-446F-966C-248378B7B965Q36245680-3DF62AE0-CF89-4D07-A5BF-84A94DF602DFQ36421845-6B17DD3D-C894-4EC5-B920-189231D4E44DQ36434501-C6E02F6F-134C-4BA7-A1D4-B9103A39311FQ36504380-5A0101EF-AD10-4E43-A455-3AB692CA7090Q36528220-FF27ADF7-1BFC-4162-8918-84E21D44DDD5Q36559044-91AE736E-A3C1-4387-A727-0642F9D075BCQ36591665-4B6555E7-59C7-4DCE-B9EA-E35C87C18E09Q37006640-7804BE23-7C6C-462F-AFC5-9C4B91F9DF4DQ37080228-8CE417EE-A21C-48D3-A9B5-2D33C49B0560Q37329526-5922A655-CF48-4D41-A678-A73613486B36Q37410392-A3495E38-A10F-42E8-ACFE-0F89792A3033Q37475947-CDE5084E-6CC5-4D79-978A-CF7AB3E22079Q37522796-DD3697E1-1F9A-438C-B650-20048344E28EQ37579105-F9E8B6E7-1699-4DF0-92F0-7B67F7F7688EQ37689760-43899FA0-9081-4E0F-8A35-C2A52DCB86C4Q37704799-06826C30-291F-4B63-BAFC-064353A1278FQ37819549-5015E14C-B007-4800-9ABF-9706F269F20AQ37896133-4B58D3C5-ACDB-4CE2-92A1-69F821E44583Q38148751-DE9FB844-4455-4325-9B93-8B9B571AB55C
P2860
Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Proposed preliminary core set ...... athic inflammatory myopathies.
@ast
Proposed preliminary core set ...... athic inflammatory myopathies.
@en
Proposed preliminary core set ...... athic inflammatory myopathies.
@nl
type
label
Proposed preliminary core set ...... athic inflammatory myopathies.
@ast
Proposed preliminary core set ...... athic inflammatory myopathies.
@en
Proposed preliminary core set ...... athic inflammatory myopathies.
@nl
prefLabel
Proposed preliminary core set ...... athic inflammatory myopathies.
@ast
Proposed preliminary core set ...... athic inflammatory myopathies.
@en
Proposed preliminary core set ...... athic inflammatory myopathies.
@nl
P2093
P50
P356
P1433
P1476
Proposed preliminary core set ...... athic inflammatory myopathies.
@en
P2093
C Morrison
C Pilkington
International Myositis Outcome Assessment Collaborative Study Group
P304
P356
10.1093/RHEUMATOLOGY/40.11.1262
P577
2001-11-01T00:00:00Z